



ASX RELEASE (11 NOVEMBER 2019)

Manufacturing Permit Received for Southport Facility

Production commencing immediately to support +250,000 Australian patients and export market

Key Points:

- Medicinal Cannabis Manufacture Permit for Southport Facility received
- Permit enables Southport Facility to receive medicinal cannabis plant material from licenced and permitted growers
- THC Global to immediately commence Australian medicinal cannabis medicines production
- Southport Facility can support a minimum of 250,000 Australian patients with affordable Australian produced medicines as well as supplying the global export market
- Capability to produce packaged and bulk medicinal cannabis from the Southport Facility
- Major milestone for THC Global and the Australian medicinal cannabis industry with the largest pharma bio-floral extraction facility now operating and only cannabis extractor of this scale

THC Global Group Limited (THC Global or the Company) (ASX:THC) advises that the Company has been granted a Manufacture Permit from the Australian Office of Drug Control for the Company's Southport Manufacturing Facility (the **Southport Facility**).

The Manufacture Permit allows the Company to now accept medicinal cannabis plant material from any Australian licenced and permitted cultivator, including from the Company's own cultivation facilities, and to immediately commence production of Australian medicinal cannabis medicines.

With the granting of the Manufacture Permit for the Southport Facility, THC Global now has the largest extraction capacity for medicinal cannabis in Australia, with the capability to support a minimum of 250,000 Australian patients in addition to having excess capacity for the global export market.

THC Global will be able to produce both packaged and bulk medicinal cannabis from the Southport Facility. The Company expects product validation to commence shortly, and be completed in December, supporting a commercial launch in early 2020.

Chief Executive Officer, Ken Charteris, commented:

"This is a major milestone for THC Global, and for the Australian medicinal cannabis industry as a whole, with THC Global now able to operate the largest pharmaceutical bio-floral extraction facility in the Southern Hemisphere. Our scale and technology will enable us to offer patients a higher quality, more consistent cannabis medicine at a significantly lower cost than the current imported products available to Australian patients".

The receipt of the Manufacture Permit for the Southport Facility confirms that the Company has now met all the regulatory steps set by the Australian Office of Drug Control prior to commencing the processing of medicinal cannabis at the Southport Facility. In addition to the Company's earlier receipt of Schedule 4 pharmacy medicines and Schedule 8 controlled substances manufacture and wholesale licences, THC Global is now fully licenced and permitted for medicinal cannabis production at the Southport Facility. These approvals include use of the Company's on-site product testing laboratory which will significantly reduce ongoing research and development costs.



For further information, please contact:



Ken Charteris
Chief Executive Officer
e: ceo@thc.global

Henry Kinstlinger
Company Secretary
e: corporate@thc.global
p: +61 2 8644 0601

Sonny Didugu
Investors & Media
e: media@thc.global
p: +61 2 8088 4760

THC Global Group Limited (ASX: THC) thc.global

THC Global operates under a 'Farm to Pharma' pharmaceutical model, now holding all three key cannabis licences being a Cannabis Research Licence, a Medicinal Cannabis Licence (Cultivation), and two Manufacture Licences through its domestic medicinal cannabis subsidiaries THC Pharma and Canndeo. THC Global's main facility, the Southport Manufacturing Facility is the largest pharmaceutical bio-floral extraction facility in the Southern Hemisphere. The Southport Facility is licenced and permitted, including holding Schedule 8 controlled substances and Schedule 4 pharmacy medicines licences.

THC Global is in prime position to commence medicinal cannabis production to service both domestic patients and the global export market. In addition to its core Australian medicinal cannabis assets, THC Global has a significant Canadian presence. THC Global's hydroponics equipment division, Crystal Mountain, is a revenue generating manufacturer, wholesaler, and retailer of hydroponics equipment and supplies for cannabis cultivation. THC Global also owns Canndeo Canada, a holder of property in Nova Scotia, Canada being developed into a large scale cannabis production site.